Synektik Valuation Multiples

Synektik is valued at $663M as of November 2026, a 2.8x revenue multiple. In the last 12 months, Synektik revenue was $234M and Synektik EBITDA was $61M.

Synektik Overview

About Synektik

Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.


Founded

2011

HQ

Poland

Employees

144

Financials (LTM)

Revenue: $234M
EBITDA: $61M

EV

$654M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Synektik Financials

Synektik reported last 12-month revenue of $234M and EBITDA of $61M.

In the same LTM period, Synektik generated $89M in gross profit, $61M in EBITDA, and $43M in net income.

Revenue (LTM)


Synektik P&L

In the most recent fiscal year, Synektik reported revenue of $170M and EBITDA of $45M.

Synektik is profitable as of last fiscal year, with gross margin of 36%, EBITDA margin of 26%, and net margin of 15%.

See analyst estimates for Synektik
LTMLast FY202320242025202620272028
Revenue$234M$170M$156M$179M$186M
Gross Profit$89M$61M$47M$62M$67M
Gross Margin38%36%30%34%36%
EBITDA$61M$45M$30M$44M$48M
EBITDA Margin26%26%19%25%26%
EBIT Margin23%23%17%22%23%
Net Profit$43M$26M$20M$26M$30M
Net Margin18%15%13%15%16%
Net Debt-($15M)---

Financial data powered by Morningstar, Inc.

Synektik Stock Performance

Synektik has current market cap of $663M, and enterprise value of $654M.

Market Cap Evolution


Synektik's stock price is $77.78.

Synektik share price decreased by 6.4% in the last 30 days, and increased by 2.1% in the last year.

Synektik has an EPS (earnings per share) of $3.01.

See more trading valuation data for Synektik
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$654M$663M-2.4%-6.4%-13.5%2.1%$3.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Synektik Valuation Multiples

Synektik trades at 2.8x EV/Revenue multiple, and 10.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Synektik

EV / Revenue (LTM)


Synektik Financial Valuation Multiples

As of November 19, 2026, Synektik has market cap of $663M and EV of $654M.

Synektik has a P/E ratio of 15.5x.

LTMLast FY202320242025202620272028
EV/Revenue2.8x3.8x4.2x3.6x3.5x
EV/EBITDA10.8x14.7x21.7x14.7x13.5x
EV/EBIT11.9x16.4x24.5x16.5x15.1x
EV/Gross Profit7.3x10.8x13.9x10.6x9.7x
P/E15.5x25.9x32.9x25.2x22.4x
EV/FCF8.5x40.0x44.1x42.8x16.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Synektik Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Synektik Margins & Growth Rates

Synektik grew revenue by 37% and EBITDA by 34% in the last fiscal year.

In the most recent fiscal year, Synektik reported gross margin of 36%, EBITDA margin of 26%, and net margin of 15%.

See estimated margins and future growth rates for Synektik

Synektik Margins

Last FY202420252026202720282029
Gross Margin36%34%36%39%
EBITDA Margin26%25%26%26%
EBIT Margin23%22%23%24%
Net Margin15%15%16%19%
FCF Margin10%9%22%31%

Synektik Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth37%15%3%27%
Gross Profit Growth43%31%9%36%
EBITDA Growth34%47%9%27%
EBIT Growth36%48%10%28%
Net Profit Growth62%30%13%48%
FCF Growth398%3%163%80%

Data powered by FactSet, Inc. and Morningstar, Inc.

Synektik Operational KPIs

Synektik's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.1M for the same period.

Synektik's Rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Synektik's Rule of X is 93% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Synektik
LTMLast FY202320242025202620272028
Rule of 4032%53%---
Bessemer Rule of X41%93%---
Revenue per Employee-$1.2M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue8%8%7%8%8%
G&A Expenses to Revenue3%4%-4%3%
R&D Expenses to Revenue0%0%4%1%0%
Opex to Revenue-12%13%12%12%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Synektik Competitors

Synektik competitors include QuidelOrtho, SD Biosensor, Delcath Systems, Sunmax Biotechnology, Xvivo Perfusion, Medistim, Bioventus, Sight Sciences, Nanosonics and Tactile Medical.

Most Synektik public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
QuidelOrtho$2.7B($485M)1.3x1.4x(7.4x)6.7x
SD Biosensor$533M($525M)1.2x-(1.2x)-
Delcath Systems$85M$939K6.8x5.2x620.9x22.2x
Sunmax Biotechnology$62M$34M10.0x-18.3x-
Xvivo Perfusion$80M$10M7.4x6.2x57.7x30.2x
Medistim$73M$24M8.1x7.0x24.4x21.9x
Bioventus$568M$99M1.7x1.7x9.9x8.1x
Sight Sciences$77M($33M)7.3x6.2x(17.2x)(32.7x)

This data is available for Pro users. Sign up to see all Synektik competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Synektik

When was Synektik founded?Synektik was founded in 2011.
Where is Synektik headquartered?Synektik is headquartered in Poland.
How many employees does Synektik have?As of today, Synektik has over 144 employees.
Is Synektik publicly listed?Yes, Synektik is a public company listed on Warsaw Stock Exchange.
What is the stock symbol of Synektik?Synektik trades under SNT ticker.
When did Synektik go public?Synektik went public in 2011.
Who are competitors of Synektik?Synektik main competitors include QuidelOrtho, SD Biosensor, Delcath Systems, Sunmax Biotechnology, Xvivo Perfusion, Medistim, Bioventus, Sight Sciences, Nanosonics, Tactile Medical.
What is the current market cap of Synektik?Synektik's current market cap is $663M.
What is the current revenue of Synektik?Synektik's last 12 months revenue is $234M.
What is the current revenue growth of Synektik?Synektik revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Synektik?Current revenue multiple of Synektik is 2.8x.
What is the current EBITDA of Synektik?Synektik's last 12 months EBITDA is $61M.
What is Synektik's EBITDA margin?Synektik's last 12 months EBITDA margin is 26%.
What is the current EV/EBITDA multiple of Synektik?Current EBITDA multiple of Synektik is 10.8x.
What is the current FCF of Synektik?Synektik's last 12 months FCF is $77M.
What is Synektik's FCF margin?Synektik's last 12 months FCF margin is 33%.
What is the current EV/FCF multiple of Synektik?Current FCF multiple of Synektik is 8.5x.
How many companies Synektik has acquired to date?Synektik hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Synektik has invested to date?Synektik hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Synektik

Lists including Synektik

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial